Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Nexentis Technologies' wholly owned subsidiary, MitoCareX Bio Ltd., has completed its internal prioritization process and selected a candidate SLC transport protein for an upcoming drug discovery campaign. This decision follows broad structural analysis enabled by the proprietary MITOLINE® algorithm, reflecting tangible progress in Nexentis' drug d…